it really is understated that Jazz pharma is following us closely. and we are one of the only companies that have done a head-to-head with the leading FDA-approved product which is currently making $1B p.a.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
